The incidence of non-Hodgkin's lymphoma in the elderly continues to increase. There has been a tendency among some treating physicians to minimize appropriate workup and treatment, which may produce a negative effect on outcomes.
Methods
Several characteristics of non-Hodgkin's lymphoma in the elderly are reviewed, including classification and staging, pathophysiology, clinical presentation, and treatment strategies.
Results
The Working Formulation remains the principal classification used. In older and younger individuals, the prevalence of histologic subtypes and the stage at presentation are similar. Regardless of the regimen chosen, doxorubicin or mitoxantrone should be included if optimal responses are to be obtained. New purine analogs extend the therapeutic armamentarium.
Conclusions
Advanced age and comorbidities can impair the capability for treatments to control non-Hodgkin's lymphoma. To enhance results, more studies that focus on the elderly are needed on drug combinations and the newer purine analogs.
Get full access to this article
View all access options for this article.
References
1.
BaranovskyA., MyersM.H.Cancer incidence and survival in patients 65 years of age and older. CA Cancer J Clin.1986; 36: 26–41.
2.
DevesaS.S., FearsT.Non-Hodgkin's lymphoma time trends: United States and International Data. Cancer Res.1992; 52(suppl 19): 5432s–5440s.
3.
RiesL.A.G., HankeyB.F., MillerB.A.Cancer Statistics Review 1973–1988. Bethesda, Md: National Cancer Institute; NIH publication 91–2789: II.34–II.35; 1991.
4.
NamboodiriK.K., HarrisR.E.Hematopoietic and lymphoproliferative cancer among male veterans using the Veterans Administration medical system. Cancer.1991; 68: 1123–1130.
5.
LevineA.M., ShibataD., Sullivan-HalleyJ.Epidemiological and biological study of acquired immunodeficiency syndrome-related lymphoma in the County of Los Angeles: preliminary results. Cancer Res.1992; 52(suppl 19): 5482s–5484s.
6.
StansfeldA.G., DieboldJ., NoelH.Updated Kiel classification for lymphomas. Lancet.1988; 1: 292–293.
7.
LukesR.J., CollinsR.D.Immunologic characterization of human malignant lymphomas. Cancer.1974; 34(suppl): 1488–1503.
8.
Non-Hodgkin's Lymphoma Pathologic Classification Project.National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer.1982; 49: 2112–2135.
9.
HarrisN.L., JaffeE.S., SteinH.A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood.1994; 84: 1361–1392.
10.
HellmanS., JaffeE.S., DeVitaV.T.Jr. Hodgkin's disease. In: DeVitaV.T., HellmanS., RosenbergS.A., eds. Cancer, Principles and Practice of Oncology.Philadelphia: JB Lippincott; 1989: 1696–1740.
11.
The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive lymphoma. N Engl J Med.1992; 329: 987–994.
12.
NewellG.R., CabanillasF.G., HagemeisterF.J.Incidence of lymphoma in the US classified by the Working Formulation. Cancer.1987; 59: 857–861.
13.
WhislerR.L., WilliamsJ.W.Jr, NewhouseY.G.Human B cell proliferative responses during aging: reduced RNA synthesis and DNA replication after signal transduction by surface immunoglobulins compared to B cell antigenic determinants CD20 and CD40. Mech Ageing Dev.1991; 61: 209–222.
14.
BeckmanI., DimopoulosK., XuX.N.T cell activation in the elderly: evidence for specific deficiencies in T cell/accessory cell interactions. Mech Ageing Dev.1990; 51: 265–276.
15.
KlinmanN.R.Discussion: aging and the expression of the B cell repertoire. Aging: Immunol Infect Dis.1990; 2: 139–142.
16.
LevineP.H., HooverR.The emerging epidemic of non-Hodgkin's lymphoma: current knowledge regarding etiological factors. Cancer Epidemiol Biomark Prev.1992; 1: 515–517.
17.
PearceN., BethwaiteP.Increasing incidence of non-Hodgkin's lymphoma: occupational and environmental factors. Cancer Res.1992; 52(suppl 19): 5496s–5500s.
CarboneA., VolpeR., GloghiniA.Non-Hodgkin's lymphoma in the elderly. I. Pathologic features at presentation. Cancer.1990; 66: 1991–1994.
20.
BallesterO.F., MoscinskiL., SpiersA.Non-Hodgkin's lymphoma in the older person: a review. J Am Geriatr Soc.1993; 41: 1245–1254.
21.
JaffeE.S., RaffeldM., MedeirosL.J.An overview of the classification of non-Hodgkin's lymphomas: an integration of morphological and phenotypical concepts. Cancer Res.1992; 52(suppl 19): 5447s–5452s.
22.
ChenM.G., ProsnitzL.R., Gonzalez-ServaA.Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma. Cancer. 1979; 43: 1245–1254.
23.
MacKintoshF.R., ColbyT.V., PodolskyW.J.Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer.1982; 49: 586–595.
24.
SimonR., DurrlemanS., HoppeR.T.The Non-Hodgkin Lymphoma Pathology Classification Project: long-term follow-up of 1153 patients with non-Hodgkin lymphomas. Ann Intern Med.1988; 109: 939–945.
25.
DollD.C., WeissR.B.Malignant lymphoma of the testis. Am J Med.1986; 81: 515–524.
26.
LyonsM.K., O'NeillB.P., MarshW.R.Primary spinal epidural non-Hodgkin's lymphoma: report of eight patients and review of the literature. Neurosurgery.1992; 30: 675–680.
27.
BurkeJ.S., HoppeR.T., CibullM.L.Cutaneous malignant lymphoma: a pathologic study of 50 cases with clinical analysis of 37. Cancer.1981; 47: 300–310.
JolyP., CharlotteF., LeibowitchM.Cutaneous lymphomas other than mycosis fungoides: follow-up study of 52 patients. J Clin Oncol.1991; 9: 1994–2001.
30.
WillemzeR., RuiterD.J., Van VlotenW.A.Reticulum cell sarcomas (large cell lymphomas) presenting in the skin: high frequency of true histiocytic lymphoma. Cancer.1982; 50: 1367–1379.
31.
KwakL.W., WilsonM., WeissL.M.Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. J Clin Oncol.1991; 9: 1426–1431.
32.
ChristenssonB., TribukaitB., LinderI.L.Cell proliferation and DNA content in non-Hodgkin's lymphoma: flow cytometry in relation to lymphoma classification. Cancer.1986; 58: 1295–1304.
33.
HermanC.J., DuqueR.E., HedleyD.DNA cytometry in cancer prognosis. PPO Updates.1993; 7: 1–8.
OffitK., ChagantiR.S.Chromosomal aberrations in non-Hodgkin's lymphoma: biologic and clinical correlations. Hematol Oncol Clin North Am.1991; 5: 853–869.
36.
LukeisR., JunejaS., TanL.Association of abnormalities of chromosome 11 with t(14;18) in diffuse non-Hodgkin's lymphoma. Cancer Genet Cytogenet.1994; 78: 36–39.
37.
StaniJ.Cytologic diagnosis of reactive lymphadenopathy in fine needle aspiration biopsy specimens. Acta Cytol.1987; 31: 8–13.
38.
LittleJ.V., FoucarK., HorvathA.Flow cytometric analysis of lymphoma and lymphoma-like disorders. Semin Diagn Pathol.1989; 6: 37–54.
39.
CossmanJ., UppenkampM., SundeenJ.Molecular genetics and the diagnosis of lymphoma. Arch Pathol Lab Med.1988; 112: 117–127.
40.
KaplanW.D., JochelsonM.S., HermanT.S.Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol.1990; 8: 1966–1970.
41.
AlkanS., KarcherD.S.Low grade lymphomas in the elderly. Ann Clin Lab Sci.1995; 25: 218–227.
42.
WeisdorfD.J., AndersenJ.W., GlickJ.H.Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. J Clin Oncol.1992; 10: 942–947.
43.
KimbyE., BjörkholmM., GahrtonG.Chlorambucil/prednisone vs CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol.1994; 5(suppl 2): 67–71.
44.
DanaB.W., DahlbergS., NathwaniB.N.Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapyJ Clin Oncol.1993; 11: 644–651.
DixonD.O., NeilanB., JonesS.E.Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group Experience. J Clin Oncol.1986; 4: 295–305.
47.
Solal-CelignyP., ChastangC., HerreraA.Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. Am J Med.1987; 83: 1075–1079.
48.
VoseJ.M., ArmitageJ.O., WeisenburgerD.D.The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol.1988; 6: 1838–1844.
49.
ShippM.A.Prognostic factors in aggressive non-Hodgkin's lymphoma: who has “high-risk” disease?Blood.1994; 83: 1165–1173.
50.
FisherR.I., GaynorE.R., DahlbergS.Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med.1993; 328: 1002–1006.
51.
GaynorE.R., DahlbergS., FisherR.I.Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma: an analysis of SWOG-8516 (INT 0067), the National High Priority Lymphoma Study. A randomized comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B. Proc Annu Meet Am Soc Clin Oncol.1994; 13: 370. Abstract 1250.
52.
AllenA.The cardiotoxicity of chemotherapeutic drugs. Semin Oncol.1992; 19: 529–542.
53.
SonneveldP., de RidderM., van der LelieH.Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol.1995; 13: 2530–2539.
54.
BezwodaW, RastogiR.B., Erazo VallaA.Long-term results of a multicentre randomized, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Eur J Cancer.1995; 31A: 903–911.
55.
PavlovskyS., SantarelliM.T., ErazoA.Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP. Ann Oncol.1992; 3: 205–209.
56.
SpeyerJ.L., GreenM.D., KramerE.Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med.1988; 319: 745–752.
57.
NovitzkyN., KingH.S., JohnsonC.Treatment of aggressive non-Hodgkin's lymphoma in the elderly. Am J Hematol1995; 49: 103–108.
58.
ChaoN.J., RosenbergS.A., HorningS.J.CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood.1990; 76: 1293–1298.
59.
NeillyI.J., OgstonM., BennettB.High grade non-Hodgkin's lymphoma in the elderly: 12-year experience in the Grampian Region of Scotland. Hematol Oncol.1995; 13: 99–106.
60.
SweetenhamJ.W., ProctorS.J., BlaiseD.The Lymphoma Working Party of the European Group for Bone Marrow Transplantation. High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Ann Oncol.1994; 5(suppl 2): 155–159.
61.
SmalleyR.V., AndersenJ.W., HawkinsM.J.Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med.1992; 327: 1336–1341.
62.
ArmitageJ.O.Bone marrow transplantation in the treatment of patients with lymphoma. Blood.1989; 73: 1749–1758.
63.
BiermanP.J., ArmitageJ.O.Autologous bone marrow transplantation for non-Hodgkin's lymphoma. In: FormanS.J., BlumeK.G., ThomasE.D., eds. Bone Marrow Transplantation.Cambridge, Mass: Blackwell Scientific Publications; 1994: 683–695.
64.
FieldsK.K., BallesterO.F., GoldsteinS.C.Age effects in patients undergoing autologous bone marrow or peripheral blood stem cell transplantation. Proc Annu Meet Am Soc Clin Oncol.1996; 15: 506.
65.
ShankW.A.Jr, BalducciL.Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older subjects. J Am Geriatr Soc.1992; 40: 151–154.
66.
SpeyerJ.L., GreenM.D., Zeleniuch-JacquotteA.ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol.1992; 10: 117–127.
67.
PettengellR., GurneyH., RadfordJ.A.Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood.1992; 80: 1430–1436.
HoffmanM., TallmanM.S., HakimianD.2-chloro-deoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol.1994; 12: 788–792.
70.
HickishT., SerafinowskiP., CunninghamD.2-chloro-deoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer.1993; 67: 139–143.
71.
WeissG.R., KuhnJ.G., RizzoJ.A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. Cancer Chemother Pharmacol.1995; 35: 397–402.
HochsterH.S., KimK.M., GreenM.D.Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol.1992; 10: 28–32.
74.
RedmanJ.R., CabanillasF., VelasquezW.S.Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol.1992; 10: 790–794.
75.
ZinzaniP.L., LauriaF., RondelliD.Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol.1993; 4: 575–578.
76.
Solal-CélignyP., BriceP., BrousseN.Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol.1996; 14: 514–519.
77.
ByrdJ.C., HargisJ.B., KesterK.Fludarabine therapy for lymphoid malignancies is associated with a high number of opportunistic pulmonary infections. Blood.1993; 82(suppl 1): 138a.
78.
WijermansP.W., GerritsW.B., HaakH.L.Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol.1993; 50: 292–296.
79.
CummingsF.J., KimK., NeimanR.S.Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol.1991; 9: 565–571.
80.
SavenA., PiroL.D.The role of nucleosides in the treatment of CLL. Contemp Oncol.1993; 3: 34–41.
81.
O'BrienM.E., MatutesE., CunninghamD.Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience. Leuk Lymphoma. 1994: 14: 17–23.
